Drug name - Farydak

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(5 years from now)

CN102584673B SECURA Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Jun, 2027

(4 years from now)

CN101641328B SECURA Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Jun, 2027

(4 years from now)

CN101641328A SECURA Polymorphs Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Jun, 2027

(4 years from now)

CN102584673A SECURA Polymorphic Substance Of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Ly) Ethyl] Amino] Methyl] Phenyl]-2E-2-Acrylamide
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma Jun, 2028

(5 years from now)

Drugs and Companies using PANOBINOSTAT LACTATE ingredient

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE CAPSULE;ORAL Discontinued
EQ 15MG BASE CAPSULE;ORAL Discontinued
EQ 20MG BASE CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.